Abeona Therapeutics Inc. - Common Stock (ABEO)
2.4550
-0.0850 (-3.35%)
NASDAQ · Last Trade: Nov 10th, 8:52 PM EST
News & Press Releases
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
CLEVELAND, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in November 2026:
By Abeona Therapeutics Inc. · Via GlobeNewswire · November 10, 2026
Abeona Therapeutics (ABEO) Q3 2026 Earnings Call Transcriptfool.com
Management lays out manufacturing targets and a new pipeline asset's path to Phase III.
Via The Motley Fool · November 9, 2026
US Session Top Movers: FISN, XHLD, TLS Lead Gainers; ZURA, SOC, PLCE Lead Loserschartmill.com
Via Chartmill · November 9, 2026
Top Movers Today: MF Gains 89.56%, ZURA Falls 72.98%chartmill.com
Via Chartmill · November 9, 2026
What Abeona Therapeutics (ABEO) Said on Its Q3 Earnings Callmarketbeat.com
Abeona Therapeutics (NASDAQ:ABEO) reported higher ZEVASKYN revenue for the third quarter of 2026 and announced the acquisition of a late-stage drug candidate for eosinophilic esophagitis, as it seeks to expand beyond its first commercial product.
Net revenue from ZEVASKYN, the company’s treatment f
Via MarketBeat · November 9, 2026
US Gap-Up and Gap-Down Movers for the Nov. 9, 2026 Sessionchartmill.com
Via Chartmill · November 9, 2026
Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress
– Q3 net ZEVASKYN revenue of $13.5 million, up 18% sequentially over Q2 –
By Abeona Therapeutics Inc. · Via GlobeNewswire · November 9, 2026
Abeona Therapeutics® Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $30 Million Private Placement
- Adds a once-daily, oral therapy candidate for eosinophilic esophagitis with FDA Orphan Drug and Fast Track Designations –
By Abeona Therapeutics Inc. · Via GlobeNewswire · November 9, 2026
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
By Abeona Therapeutics Inc. · Via GlobeNewswire · November 2, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · October 6, 2026
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Ohio, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
By Abeona Therapeutics Inc. · Via GlobeNewswire · October 2, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 29, 2026
Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwrightmarketbeat.com
Abeona Therapeutics (NASDAQ:ABEO) highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the H.C. Wainwright 28th Annual conference.
Madhav Vasanthavada, Abeona’s senior vice president
Via MarketBeat · September 22, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 22, 2026
Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentummarketbeat.com
Abeona Therapeutics (NASDAQ:ABEO) executives outlined the early commercial rollout of ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the Morgan Stanley Global Healthcare Conference. Management emphasized that the launch requires a
Via MarketBeat · September 22, 2026
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
- FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona’s foundational R&D and clinical development efforts -
By Abeona Therapeutics Inc. · Via GlobeNewswire · September 18, 2026
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced the activation of University of Florida Health (UF Health) in Gainesville, Florida, as the eighth Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN is the first and only autologous gene-modified cellular sheets for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).
By Abeona Therapeutics Inc. · Via GlobeNewswire · September 16, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 15, 2026
ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or “the Company”) (NASDAQ: ABEO) for violations of the securities laws.
By Schall, Brown & Schwartz LLP · Via Business Wire · September 8, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 8, 2026
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
CLEVELAND, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2026:
By Abeona Therapeutics Inc. · Via GlobeNewswire · September 2, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 1, 2026
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
By Abeona Therapeutics Inc. · Via GlobeNewswire · September 1, 2026
Abeona (ABEO) Q2 2026 Earnings Call Transcriptfool.com
ZEVASKYN revenue surged 31% to $11.4 million as treatment network expanded.
Via The Motley Fool · August 20, 2026
Abeona Therapeutics Q2 2026 Earnings Call Transcriptbenzinga.com
Abeona Therapeutics (NASDAQ:ABEO) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data
Via Benzinga · August 13, 2026